Detalles de la búsqueda
1.
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients.
Int J Cancer;
150(7): 1166-1173, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34605002
2.
Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel.
BMC Med;
20(1): 48, 2022 01 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35101049
3.
Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review.
Int J Mol Sci;
22(10)2021 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34067977
4.
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer.
Br J Cancer;
123(6): 982-987, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32669676
5.
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Prostate;
79(11): 1211-1220, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31251826
6.
Reclassification of good-risk seminoma: prognostic factors, novel biomarkers and implications for clinical management.
Future Oncol;
15(12): 1347-1352, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30880465
7.
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer.
BMC Cancer;
18(1): 1267, 2018 Dec 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-30567527
8.
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.
Anticancer Drugs;
29(7): 705-709, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29846246
9.
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.
Prostate;
77(9): 1012-1019, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28429372
10.
A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer.
Oncologist;
22(7): 784-e74, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28546463
11.
Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations.
Genet Med;
17(5): 391-5, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25188872
12.
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
Future Oncol;
11(21): 2881-91, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26436290
13.
Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST).
BMC Cancer;
14: 685, 2014 Sep 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-25239601
14.
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study.
Eur Urol Open Sci;
61: 44-51, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38384439
15.
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care.
Prostate Cancer Prostatic Dis;
2024 Feb 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38347113
16.
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study.
Eur Urol Oncol;
2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38575409
17.
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations.
Clin Exp Metastasis;
41(2): 117-129, 2024 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38363410
18.
Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors.
Front Immunol;
14: 1118610, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36860862
19.
The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer.
Cancers (Basel);
15(5)2023 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36900394
20.
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients.
Front Oncol;
13: 1221096, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37664032